Afleveringen
-
Systemic Sclerosis (SSc) is a painful and debilitating disease that our patients suffer from. However, a newly published study has concluded that there are some self-management interventions patients can engage with that have shown to improve fatigue, particularly for those newly diagnosed with SSc. Today, we review the procedures, interventions, results and conclusions of this study, titled: Effects of a Resilience-Building Energy Management Program on Fatigue and Other Symptoms in Systemic Sclerosis: A Randomized Controlled Trial, along with two of its authors, Dr. Susan L Murphy and Ms. Mary Alore, and how your patients can benefit from its lessons.
-
As the need and demand for quality care increases, time in clinic needs to become more efficient. Working smarter, not harder, is a daily challenge for all in our field. With mobile technology streamlining so much and improvements in patient reported outcome (PRO) collection among patients with rheumatoid arthritis (RA) needed, it had Dr. Daniel Solomon asking â...is there an app for that?â. Today, we review the study A Mobile Health Application Integrated in the Electronic Health Record for Rheumatoid Arthritis PatientâReported Outcomes: A Controlled Interrupted Time-Series Analysis of Impact on Visit Efficiency , recently published in Arthritis & Rheumatology. Our guest, Dr. Daniel Solomon, is our guest and the studyâs first author.
-
Zijn er afleveringen die ontbreken?
-
Recent research indicates that those who suffer from AxSpA may have some hope in protecting against events of Uveitis! Dr. Katie Bechman, first author Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis, explains her teamâs research findings and how they came to this exciting conclusion!
-
âIf I have seen further, it is because I stand on the shoulders of giantsâ Sir Isaac Newton famously stated in a letter to polymath scientist, Robert Hooke back in 1675. Today, Dr. Mary Crow, MD, aides Arthritis & Rheumatology launch a series on immunology, for rheumatologists. She is the co-author of the article Standing on Shoulders: Interferon Research, from Viral Interference to Lupus Pathogenesis and Treatment. In this episode, we stand with Dr. Crow to look back at the achievements made by brilliant minds in interferon research and analyze the unbroken line their advancements in rheumatology have led to todayâs discoveries, with more to com
-
Is there an increased risk of cancer once a patient has Scleroderma? If so, what is the risk and how does one go about showing this? Dr. Ami A Shah, Director of the Division of Rheumatology at Johns Hopkins sits down with us to explain those answers. We go over the methods, results and conclusions of the recent study Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course published in Arthritis & Rheumatology. Afterward, Dr. Shah shares with us her journey to becoming a physician-scientist and mentoring others in Scleroderma research through a K24 grant.
-
Welcome back to âJournalsâ! Our topic of discussion today comes from the manuscript Anti-Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction and our guest today is the studyâs first author, Dr. Zsuzsanna McMahan. The study recognizes that the enteric nervous system (ENS) regulates the gastrointestinal (GI) function, which is commonly impaired in those who suffer from systemic sclerosis (SSc). Dr. McMahan and her teamâs objective for this study was âto identify novel anti-ENS autoantibodies with an aim to clinically phenotype SSc GI dysfunctionâ. We sit down with Dr. McMahan and discuss the studyâs methods and discoveries. Plus, her experience transitioning from a junior to an independent investigator and what advice she can offer our young listeners for the journey along the way.
-
Dr. Tobit Steinmetz is our guest this week, author of the manuscript recently published in âArthritis and Rheumatologyâ titled: "Association of Circulating Antibody-Secreting Cell Maturity with Disease Features in Primary Sjogren's Syndrome." Dr. Steinmetz and his team endeavored to better understand the hyperactivity observed among B cells, which play a major role in Primary Sjogrenâs Syndrome (SS). To do this, he and the team examined the quantity, maturity and inflammatory properties of Antibody Secreting Cells (ASCs) in the B cell effector branch, which became the focus of the study. Tune in to hear how this was done, what their observations and conclusions were plus, Dr. Steinmetzâs insights for those looking to enter a postdoctoral position!
-
After a major event, itâs important to take stock of the causes of such an event, but just as important, on the reactions to it. No other event has challenged humanity in recent memory like COVID-19. Today we discuss the pandemic in relationship to its impact on those who suffer with rheumatic disease and examine the global response. Our guest is Dr. Evelyn Hsieh, MD, PhD, the first author of the paper: Global Perspective on the Impact of the COVID-19 Pandemic on Rheumatology and Health Equity , which was recently published in Arthritis Care & Research.
-
Sometimes, we learn more from what isnât achieved than when we achieve an expected result. Such is the case for our next guest, Dr. David R. Jayne, who is the first author of Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial , a study designed to characterize a dose-response relationship between an anti-CD40 monoclonal antibody known as Bi 655064 and complete renal response (CRR) in patients with active lupus nephritis (LN). Dr. Jayne and his research teamâs study may not have shown this dose-response relationship, but what was gained along the way surely shows the power of the negative study!
-
Knowing that glucocorticoids significantly increase the risk of fractures and is the most common cause of secondary osteoporosis, the use of the steroid has always been viewed as a doubled edged sword and âBad for the Bonesâ. This week, we welcome Dr. Giovanni Adami, first author of Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated with Low-Dose Glucocorticoids and Prevention by Anti-Osteoporosis Medications , whose goal for this study was to assess if a âsafeâ dose of glucocorticoids exists, with an attention focus on those with inflammatory rheumatic musculoskeletal diseases (iRMDs) to determine if a low enough dose of glucocorticoids can still reduce inflammatory burden and yet significantly reduce expected risk of fracture.
-
The pandemic has changed much in our worldâfrom the way we work, to the way we shop, and even the way we learn. Rheumatology wasnât immune from such changes and when medical institutions needed to adjust their practices to accommodate a changing world around them, the process by which fellowship interviews were conducted needed to change as well. Thus, a shift to the video communication platform Zoom was made.
Now, as the pioneering cohorts of the new Zoom matching process graduate, we are joined by Bharat Kumar, MD, MME, FACP, RhMSUS. Dr. Kumar has been doing a lot of research on what went well, what didnât, and what merits rethinking. Dr. Kumar is the first author of the manuscript Reimagining the Rheumatology Fellowship Interview: Using Participatory Design-Thinking Process to Create a More Applicant-Centered Experience.
-
Our next guest, Dr. Paul Monach, reviews âComplementâ, focusing on its application in the clinical setting. In his work, Dr. Monach presents a typical case with a broad differential diagnosis, then provides an overview of the complement system along with clinical diseases with complement-driven mechanisms. Dr. Shanmugam reviews this manuscript published in Arthritis & Rheumatology plus an analysis of the laboratory tests. Later in the show, Dr. Monach gives us his insights on how he combines his clinical work with his translational work in immunology and acts Chief of Immunology at the VA in Boston, Massachusetts!
-
End-stage renal disease is a dangerous reality for those who suffer from Lupus Nephritis (LN), despite improvements in immunosuppressive therapy in the last 20 years. Our next guest, Dr. Brad H Rovin, MD, FACP, FASN, is the first author of the manuscript âKidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial.â which was recently published in Arthritis & Rheumatology. This study was a post hoc analysis of the NOBILITY trial and was conducted to assess kidney-related outcomes in patients using Obinutuzumab.
-
This week on âJournalsâ, we turn our attention to a rare but challenging and heart-breaking complication of rheumatic disease, Congenital Heart Block. Sir Deryck and Lady Va Maughan Professor of Rheumatology and Director of the Division of Rheumatology at New York University School of Medicine, Dr. Jill Buyon joins us today to present her latest research âProspective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block.â.
-
This week on âJournalsâ, weâll look at not just one, but two studies that endeavored to define knee osteoarthritis (OA) through magnetic resonance imaging (MRI) imagery. The manuscripts weâll be discussing are:
Development of a Magnetic Resonance ImagingâBased Definition of Knee Osteoarthritis: Data From the Multicenter Osteoarthritis Study
Diagnostic accuracy of candidate MRI knee osteoarthritis definitions versus radiograph in an acute anterior cruciate ligament injury cohort
Our guest is lead author and social media influencer for rheumatology, Dr. Jean Liew, MD, MS (@Rheum_cat)
-
This week we welcome our next guest, Dr. John D. Pauling to âJournalsâ. Dr. Pauling is the senior author of the manuscript âAssessment of the Systemic Sclerosis-Associated Raynaudâs Phenomenon Questionnaire: Item Bank and Short Form Developmentâ, which endeavored to âdevelop, refine and score a novel patient-reported outcome instrument to assess the severity and impact of Raynaudâs Phenomenon (RP) in Systemic Sclerosis (SSc)â. In this episode, we discuss the challenges associated with measuring one of the most common disease manifestations of scleroderma, Raynaudâs, and how the Assessment of Systemic Sclerosis-Associated Raynaudâs Phenomenon (ASRAP) questionnaire was harmonious in the paperâs results and final conclusions.
-
Assessing disease activity in large vessel vasculitis can be a challenge. And as imaging techniques evolve, clinicians must evaluate how to harness new imaging modalities in clinical care. In an attempt to predict the progression of large vessel vasculitis (LVV), our next guest, Dr. Kaitlin Quinn, used the vascular activity seen on a fluorodeoxyglucose-positron emission tomography (FDG-PET) scan to determine if there is an observable association with angiographic change. Dr. Quinn, author of the study Association of 18F-FluorodeoxyglucoseâPositron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis, breaks down her study and its methods along with her observations and findings for us.
-
This week our guest is Dr. Joyce Chang, MD, MSCE, a recipient of the Lupus Foundation of Americaâs âMary Betty Stevens Young Investigator Awardâ, who shares her latest study, its methods, conclusions and career journey with us! Dr. Changâs latest study âImproving Outcomes of Pediatric Lupus Care Delivery With Provider Goal-Setting Activities and Multidisciplinary Care Modelsâ used the pediatric Lupus Care Index (pLCI) and population management strategies for improving outcomes in childhood SLE. Later, we spent some time with Dr. Chang and asked what she sought out in her first faculty appointment and how she ensured she would hit the ground running.
-
Patients with Rheumatoid Arthritis (RA) need rehabilitation to improve functional limitations and slow disability. But in what doses? Using the FORWARD databank, our next guest Dr. Kaleb Michaud, PhD, identified a cohort and gathered data on rehabilitation dose and their functional outcomes. His studyâs objective (titled: âExamining Rehabilitation Dose in Adults With Rheumatoid Arthritis: Association With Baseline Factors and Change in Clinical Outcomesâ) determine if there was a meaningful change in physical function, pain and fatigue over a six-month period when evaluating baseline factors and rehabilitation dose. This study, recently published in Arthritis Care & Research is the subject of our discussion today.
-
Photosensitivity among patients with SLE is a well-known symptom. However, what is not well-known is why. Our guest this week, Dr. J. Michelle Kahlenberg MD, PhD and team, endeavored to uncover that answer. The article, âRegulation of Photosensitivity by the Hippo Pathway in Lupus Skinâ was the result of this study, which was published in âArthritis & Rheumatologyâ earlier this year. Dr. Kahlenberg joins us for this episode to discuss the studyâs methods, results and its surprising conclusion: a novel driver was discovered!
- Laat meer zien